MaltSci 麦伴科研

Appearance

Popular Reports / rare-diseases

This report is written by MaltSci based on the latest literature and research findings

What are the mechanisms of muscular dystrophy? ​

Abstract ​

Muscular dystrophy (MD) represents a group of inherited disorders characterized by progressive muscle degeneration and weakness, resulting from genetic mutations that disrupt muscle fiber function. The pathophysiology of MD is multifaceted, involving genetic, biochemical, and cellular mechanisms that compromise muscle integrity. This review aims to elucidate the underlying mechanisms of MD, focusing on the genetic basis, including the identification of key genes such as dystrophin in Duchenne muscular dystrophy (DMD) and laminin in congenital muscular dystrophies. The role of inflammation, extracellular matrix remodeling, and impaired regeneration are also examined as critical components of disease progression. Recent advancements in molecular genetics have identified over 50 causative genes, revealing the complexity of MD and the necessity for tailored therapeutic approaches. Current and emerging therapies, including gene therapy, pharmacological interventions, and stem cell therapy, are discussed, emphasizing their potential to ameliorate the effects of muscle degeneration. Future directions in research should focus on novel therapeutic targets and biomarkers for disease progression, fostering a multidisciplinary approach to improve patient outcomes. Understanding the intricate mechanisms of MD is crucial for developing effective strategies that can enhance the quality of life for individuals affected by these disorders.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Genetic Basis of Muscular Dystrophy
    • 2.1 Overview of Key Genes
    • 2.2 Inheritance Patterns and Genetic Mutations
  • 3 Pathophysiological Mechanisms
    • 3.1 Muscle Fiber Degeneration
    • 3.2 Role of Inflammation and Immune Response
    • 3.3 Altered Muscle Regeneration
  • 4 Non-Cell Autonomous Mechanisms
    • 4.1 Extracellular Matrix Remodeling
    • 4.2 Interactions with Surrounding Tissues
  • 5 Current and Emerging Therapies
    • 5.1 Gene Therapy Approaches
    • 5.2 Pharmacological Interventions
    • 5.3 Stem Cell Therapy
  • 6 Future Directions in Research
    • 6.1 Novel Therapeutic Targets
    • 6.2 Biomarkers for Disease Progression
  • 7 Summary

1 Introduction ​

Muscular dystrophy (MD) is a collective term for a group of inherited disorders that lead to progressive muscle degeneration and weakness. These disorders arise from genetic mutations that disrupt the normal function of muscle fibers, ultimately resulting in muscle necrosis, impaired regeneration, and systemic complications. The pathophysiology of muscular dystrophy is complex, involving not only genetic and biochemical alterations but also cellular mechanisms that affect muscle integrity and function. Understanding these multifaceted mechanisms is crucial for the development of targeted therapies that can improve patient outcomes and quality of life. The exploration of genetic factors, particularly the identification of key genes such as dystrophin in Duchenne muscular dystrophy (DMD) and laminin in congenital muscular dystrophies, has provided insights into the molecular underpinnings of these disorders [1][2].

The significance of studying muscular dystrophy extends beyond the realm of genetic research; it encompasses the need to address the clinical challenges faced by patients and their families. The progressive nature of these diseases not only affects physical health but also has psychological and social implications. Patients with muscular dystrophy often experience autonomic dysfunction, cognitive impairment, and emotional distress, which complicate their clinical management [3][4]. Recent advances in molecular genetics have highlighted the importance of understanding both cell-autonomous and non-cell-autonomous mechanisms in the pathogenesis of muscular dystrophy. This includes the role of inflammatory responses and extracellular matrix remodeling, which have emerged as critical components in the disease progression [1][2].

Current research has made significant strides in elucidating the genetic basis of muscular dystrophies. Over 50 distinct genes have been identified as causative factors, with ongoing investigations aimed at uncovering the intricate molecular mechanisms linking these genetic mutations to muscle pathology [5]. Studies utilizing animal models and human genetic analyses have revealed distinct cellular processes that underlie the various phenotypes of muscular dystrophy, including muscle fiber degeneration, inflammation, and altered regenerative capacity [1][2]. These findings underscore the heterogeneity of muscular dystrophies and the need for tailored therapeutic approaches.

The organization of this review is structured to provide a comprehensive overview of the mechanisms underlying muscular dystrophy. The first section will discuss the genetic basis of muscular dystrophy, detailing key genes and their inheritance patterns. This will be followed by an exploration of the pathophysiological mechanisms, including muscle fiber degeneration, the role of inflammation and immune response, and the challenges of muscle regeneration. Next, we will examine non-cell autonomous mechanisms, focusing on extracellular matrix remodeling and interactions with surrounding tissues. The review will then highlight current and emerging therapies, such as gene therapy approaches, pharmacological interventions, and stem cell therapy. Finally, we will address future directions in research, emphasizing novel therapeutic targets and potential biomarkers for disease progression.

By elucidating the mechanisms of muscular dystrophy, this review aims to enhance our understanding of the disease and inform future research efforts. The complexity of muscular dystrophy necessitates a multidisciplinary approach, integrating genetic, biochemical, and clinical perspectives to develop effective therapeutic strategies. As we advance our knowledge in this field, we remain hopeful that continued research will lead to breakthroughs that can significantly improve the lives of those affected by muscular dystrophy.

2 Genetic Basis of Muscular Dystrophy ​

2.1 Overview of Key Genes ​

Muscular dystrophies (MD) encompass a diverse group of genetic disorders characterized by progressive degeneration and weakness of skeletal muscle. The underlying mechanisms of muscular dystrophy are primarily rooted in genetic mutations affecting various proteins essential for muscle integrity and function.

The dystrophin-glycoprotein complex (DGC) is a critical component in the pathogenesis of muscular dystrophies. Mutations in genes encoding components of the DGC disrupt the linkage between the intracellular cytoskeleton and the extracellular matrix, which is vital for maintaining muscle cell stability and integrity. This disruption leads to mechanical stress and eventual muscle degeneration [6].

Genetic studies have identified numerous causative genes associated with muscular dystrophies. For instance, defects in the gene for dystrophin, a key protein in the DGC, are implicated in Duchenne Muscular Dystrophy (DMD), a prototypical form of muscular dystrophy [1]. The genetic landscape of muscular dystrophies is vast, with over 50 distinct genes identified as contributing factors, each associated with different molecular mechanisms [5]. These mechanisms include glycosylation abnormalities, such as those affecting alpha-dystroglycan, collagen VI deficiencies, and mutations in the titin gene, among others [7].

In addition to primary mutations, secondary genetic modifiers play a significant role in the clinical variability observed in muscular dystrophies. These modifiers can influence disease progression and severity, leading to differences in phenotypes among patients with the same primary mutation. For example, factors such as the transforming growth factor-β (TGF-β) pathway have been identified as modifiers that regulate the pathophysiological context of dystrophic degeneration and regeneration [8].

The balance between muscle degeneration and regeneration is disrupted in muscular dystrophies, leading to muscle necrosis that surpasses the regenerative capacity of muscle tissue. This results in the replacement of muscle fibers with fibrotic and fatty tissue, ultimately causing muscle weakness and loss of function [2]. Furthermore, external factors, such as the extracellular matrix, also modulate the disease process, contributing to the complexity of muscular dystrophy [9].

Overall, the mechanisms underlying muscular dystrophy involve a combination of genetic mutations affecting structural proteins, regulatory pathways, and the interactions between muscle cells and their environment. Understanding these mechanisms is crucial for developing targeted therapeutic strategies aimed at ameliorating the effects of these debilitating disorders.

2.2 Inheritance Patterns and Genetic Mutations ​

Muscular dystrophies are a group of heterogeneous genetic disorders characterized by progressive degeneration and weakness of skeletal muscle. The genetic basis of these conditions is complex, involving mutations in over 50 distinct genes, which can lead to varying phenotypes and disease severity among affected individuals. The mechanisms underlying muscular dystrophy can be broadly categorized into genetic mutations and their effects on muscle function, as well as the influence of genetic modifiers.

The primary mutations responsible for muscular dystrophies often affect proteins that are crucial for muscle structure and function. For instance, Duchenne Muscular Dystrophy (DMD), the most common form, is caused by mutations in the dystrophin gene, which encodes a protein that is a key component of the dystrophin-glycoprotein complex (DGC). This complex plays a critical role in linking the intracellular cytoskeleton to the extracellular matrix, thereby maintaining muscle integrity. Defects in this complex can lead to muscle cell damage and degeneration (Rahimov & Kunkel, 2013; Kim et al., 2004).

In addition to primary mutations, there are secondary genetic modifiers that can influence the clinical presentation and progression of muscular dystrophies. These modifiers can either exacerbate or ameliorate the effects of the primary mutation. For example, studies have identified various genetic modifiers, such as osteopontin and latent TGFβ binding protein 4 (LTBP4), which can impact the pathophysiological context of dystrophic degeneration and regeneration (Quattrocelli et al., 2017). The presence of these modifiers can lead to variability in disease phenotypes, including differences in the age of loss of ambulation and the presence of cardiac defects, even among individuals with the same underlying genetic mutation (Hightower & Alexander, 2018).

Moreover, the transforming growth factor-β (TGF-β) pathway has been identified as a significant modifier in muscular dystrophy. TGF-β signaling is often upregulated in dystrophic muscle, which may result from a destabilized plasma membrane or altered extracellular matrix, contributing to muscle degeneration and fibrotic replacement (Ceco & McNally, 2013). This highlights the role of environmental factors and cellular signaling pathways in modifying disease outcomes.

The inheritance patterns of muscular dystrophies can vary widely. Some forms, such as DMD, follow an X-linked recessive inheritance pattern, affecting primarily males, while other forms may exhibit autosomal dominant or autosomal recessive inheritance. This genetic diversity underscores the complexity of muscular dystrophies and the need for comprehensive genetic analysis to understand individual cases fully.

In summary, the mechanisms of muscular dystrophy are multifaceted, involving direct genetic mutations that disrupt muscle integrity and function, as well as the influence of genetic modifiers and environmental factors that can alter disease severity and progression. Understanding these mechanisms is crucial for developing targeted therapies aimed at mitigating muscle degeneration and improving patient outcomes (Nishino & Ozawa, 2002; Bhatnagar & Kumar, 2010).

3 Pathophysiological Mechanisms ​

3.1 Muscle Fiber Degeneration ​

Muscular dystrophies are characterized by progressive muscle degeneration and weakness, primarily resulting from genetic defects that disrupt various cellular and molecular mechanisms within muscle fibers. The pathophysiological processes underlying muscle fiber degeneration involve a complex interplay of genetic mutations, cellular signaling pathways, and structural abnormalities in muscle tissue.

One of the primary mechanisms contributing to muscle fiber degeneration is the imbalance between muscle degeneration and regeneration. This imbalance leads to myofiber degeneration, which is exacerbated by the infiltration of adipose and connective tissues, replacing the lost muscle fibers [10]. In muscular dystrophies, such as Duchenne Muscular Dystrophy (DMD), the absence of dystrophin—a protein crucial for maintaining the structural integrity of muscle cell membranes—results in repeated cycles of muscle degeneration and inadequate regeneration. The degeneration is marked by muscle necrosis, which outpaces the regenerative capacity of muscle fibers, ultimately leading to the replacement of functional muscle with fibrotic and fatty tissues [[pmid:18808326],[pmid:33234495]].

Moreover, the activation of specific signaling pathways plays a significant role in the degeneration process. For instance, the transforming growth factor-β (TGF-β) pathway is notably upregulated in dystrophic muscle, contributing to fibrosis and impaired regeneration [8]. The TGF-β signaling cascade is involved in the fibrotic response and can lead to excessive collagen deposition, which further compromises muscle function [11].

Genetic modifiers also significantly influence the pathophysiology of muscular dystrophies. These modifiers can either enhance or mitigate the effects of the primary mutation responsible for muscle degeneration. For example, certain extracellular proteins have been identified as modifiers that regulate the degenerative processes in muscle, impacting how the disease manifests and progresses [9]. The variability in disease severity, even among individuals with the same primary mutation, underscores the importance of these genetic modifiers in determining the clinical outcome of muscular dystrophies [1].

At the cellular level, defects in membrane repair mechanisms have been implicated in muscle degeneration. For example, dysferlin, a protein involved in membrane repair, is mutated in some forms of muscular dystrophy, leading to compromised membrane integrity and increased susceptibility to damage during muscle contractions [12]. This defect in membrane repair not only facilitates muscle fiber degeneration but also disrupts normal muscle function.

Furthermore, the role of inflammation in muscular dystrophy cannot be overlooked. Chronic inflammation is a hallmark of dystrophic muscle, exacerbating degeneration and fibrosis. The inflammatory response can lead to the recruitment of immune cells that further contribute to muscle damage and hinder the regeneration process [11].

In summary, the mechanisms of muscle fiber degeneration in muscular dystrophy are multifaceted, involving genetic mutations, dysregulated signaling pathways, compromised membrane integrity, and inflammatory responses. These interconnected processes ultimately lead to the progressive loss of muscle function, highlighting the complexity of the pathophysiological mechanisms at play in these disorders.

3.2 Role of Inflammation and Immune Response ​

Muscular dystrophies are characterized by progressive muscle degeneration and are associated with complex pathophysiological mechanisms, prominently involving inflammation and immune responses. The role of inflammation in muscular dystrophy is multifaceted, influencing both disease progression and severity.

In Duchenne muscular dystrophy (DMD), the absence of dystrophin leads to muscle membrane fragility, which results in repeated muscle damage during contraction. This damage triggers a prolonged inflammatory response that is crucial for muscle regeneration but also exacerbates muscle injury. Neutrophils are among the first immune cells recruited to the site of muscle damage, where they release pro-inflammatory cytokines and compounds, such as myeloperoxidase and neutrophil elastase, contributing to oxidative stress and further muscle damage [13].

The immune response in muscular dystrophies is not solely a consequence of muscle damage but is also characterized by a dysregulated immune system. For instance, in DMD, the activation of CD4+ and CD8+ T cells, regulatory T cells, macrophages, and eosinophils has been documented. The severity of muscle injury correlates with the extent of immune cell infiltration, which in turn affects muscle regeneration and the replacement of muscle fibers with connective and adipose tissue [13][14].

Additionally, the immune system's response can be detrimental. Inflammatory factors such as elevated levels of cytokines can lead to chronic inflammation, which contributes to muscle fibrosis and degeneration. The presence of autoreactive T-lymphocytes and defects in central tolerance in DMD further complicate the immune landscape, suggesting that the immune response is misapplied in the context of chronic muscle injury [13][14].

Recent studies have highlighted the role of eosinophils and innate lymphoid cells (ILC2s) in muscular dystrophy. Eosinophils, often elevated in DMD, are regulated by ILC2s and contribute to the inflammatory milieu, promoting fibrosis and impairing muscle regeneration [15]. Furthermore, TLR4 has been identified as a regulator of trained immunity in a murine model of DMD, suggesting that innate immune responses are not only reactive but can also exhibit memory-like characteristics that perpetuate inflammation [16].

Overall, the interplay between inflammation and immune responses in muscular dystrophies indicates that while inflammation is essential for initiating repair processes, its chronic activation leads to detrimental effects on muscle integrity and function. This complex relationship underscores the potential for targeted immunomodulatory therapies to improve outcomes in muscular dystrophies, aiming to balance the immune response to favor regeneration over fibrosis [17][18].

3.3 Altered Muscle Regeneration ​

Muscular dystrophies are characterized by progressive muscle degeneration and insufficient regeneration, leading to significant muscle weakness and functional impairment. The pathophysiological mechanisms underlying these conditions are multifaceted, with alterations in muscle regeneration being a critical component.

One of the primary mechanisms involves the imbalance between muscle degeneration and regeneration. As muscle fibers undergo degeneration due to genetic mutations affecting proteins essential for muscle structure and function, there is a compensatory attempt at regeneration. However, this regenerative capacity is often overwhelmed by the ongoing degeneration. The replacement of lost muscle fibers with adipose and connective tissues further complicates the regenerative process, resulting in a cycle of degeneration and ineffective repair[10].

Key genes involved in muscle regeneration include MyoD, Myf5, and myogenin, which are critical for the proliferation and differentiation of satellite cells—muscle stem cells responsible for repair and regeneration. Studies have shown that while these genes are activated in response to muscle injury, their efficacy can be hampered by the pathological environment present in dystrophic muscles. For instance, the expression of the TGF-β1 gene, which plays a significant role in the fibrotic response, is activated throughout the degeneration process, suggesting that fibrosis can impede effective muscle regeneration[10].

Moreover, the role of transforming growth factor-beta (TGF-β) in muscular dystrophies has been highlighted as a modifier of disease progression. TGF-β signaling is upregulated in dystrophic muscles due to membrane destabilization and alterations in the extracellular matrix, contributing to fibrosis and further impairing muscle regeneration. This dysregulation not only exacerbates muscle degeneration but also modifies the overall disease severity and progression[8].

Additionally, the immune response plays a significant role in the regeneration process. In chronic conditions like muscular dystrophy, the immune response can become maladaptive, exacerbating muscle damage instead of facilitating repair. For instance, macrophages and other immune cells can release inflammatory cytokines that lead to further degeneration and fibrosis, hindering the regenerative capacity of the muscle[19].

In summary, the mechanisms of muscular dystrophy involve a complex interplay between degeneration and regeneration processes. The failure of muscle regeneration is influenced by genetic mutations, the activation of fibrotic pathways such as TGF-β, and maladaptive immune responses, all of which contribute to the progressive loss of muscle mass and function characteristic of these disorders. Understanding these mechanisms is crucial for developing therapeutic strategies aimed at enhancing muscle repair and mitigating the effects of degeneration.

4 Non-Cell Autonomous Mechanisms ​

4.1 Extracellular Matrix Remodeling ​

Muscular dystrophies (MD) are characterized by progressive muscle degeneration, and their pathophysiology involves complex interactions between various cellular and extracellular components. One critical aspect of muscular dystrophy is the role of the extracellular matrix (ECM) and its remodeling, which significantly impacts muscle function and regeneration.

The ECM provides structural support to muscle fibers and plays a vital role in signaling, force transmission, and maintaining muscle integrity. In muscular dystrophies, mutations in genes encoding ECM proteins can lead to pathological changes that disrupt these functions. For instance, defects in ECM components can result in loss of adhesion within the myomatrix, leading to progressive muscle weakness and degeneration [20]. This is particularly evident in conditions such as COL6-related and LAMA2-related dystrophies, where mutations affect the ECM and basement membrane proteins, contributing to muscle disease [21].

One of the primary mechanisms of muscular dystrophy involves ECM remodeling, which can either support muscle regeneration or facilitate fibrosis and degeneration. In dystrophic muscles, ECM remodeling is often chronic and maladaptive, resulting in excessive deposition of fibrotic tissue that obstructs regenerative efforts [22]. This process is exacerbated by the activation of various signaling pathways, including those involving connective tissue growth factor (CTGF or CCN2), which can influence collagen organization and contribute to fibrosis [22].

Moreover, the presence of specific ECM components can alter myoblast behavior, affecting their motility and differentiation. Studies have shown that decellularized matrices from dystrophic muscles exhibit distinct compositions that can differentially impact myoblast activity. For example, dystrophin-deficient matrices were found to inhibit myoblast mobility, while matrices from dysferlin-deficient muscles enhanced myoblast movement and differentiation [23]. These findings underscore the importance of ECM composition in dictating cellular responses during muscle repair and regeneration.

Additionally, the pathological remodeling of the ECM in muscular dystrophies is associated with the accumulation of matricellular proteins, which can modulate the interaction between muscle cells and the ECM. Such interactions are crucial for maintaining muscle homeostasis and function. The gradual accumulation of collagen and associated proteins is a key feature of many neuromuscular disorders, including Duchenne muscular dystrophy (DMD), where fibrosis correlates with poor motor outcomes [24].

In summary, the mechanisms underlying muscular dystrophy are significantly influenced by ECM remodeling. This process involves alterations in ECM composition and structure that disrupt normal muscle function, hinder regeneration, and promote fibrosis. Understanding these non-cell autonomous mechanisms provides insights into potential therapeutic targets aimed at mitigating the effects of muscular dystrophies and improving muscle health.

4.2 Interactions with Surrounding Tissues ​

Muscular dystrophies are a group of genetically inherited disorders characterized by progressive degeneration of skeletal muscle, with several forms also affecting cardiac muscle. The primary defect in these diseases arises from mutations in myocyte proteins that are crucial for cellular structure and function. However, beyond the intrinsic cellular defects, a growing body of evidence suggests that non-cell autonomous mechanisms, particularly interactions with surrounding tissues, play a significant role in the pathogenesis of muscular dystrophy.

One critical aspect of non-cell autonomous mechanisms involves the loss of neuronal nitric oxide synthase (nNOS) in dystrophic muscle. This deficiency is implicated in a variety of pathological features affecting muscle and its interaction with other tissues, including misregulation of muscle development, impaired blood flow, increased fatigue, inflammation, and fibrosis. Normalizing nitric oxide (NO) production has been proposed as a potential therapeutic strategy, as it could attenuate various aspects of muscular dystrophy pathology through multiple regulatory pathways. However, the specific contributions of nNOS loss from the sarcolemma versus total nNOS loss remain uncertain (Tidball and Wehling-Henricks, 2014) [25].

Additionally, muscular dystrophies are associated with significant immune responses that can exacerbate muscle degeneration. The regenerative potential of mesenchymal stem/stromal cells (MSCs) of bone marrow origin has been recognized, highlighting their ability to differentiate into various tissues and their immunomodulatory properties. These cells can interact with the inflammatory environment of dystrophic muscle, which plays a crucial role in muscle regeneration and repair. The inflammatory milieu can affect the function and survival of muscle-resident stem/progenitor cells, further complicating the disease process (Klimczak et al., 2018) [26].

Moreover, the mechanisms of muscle degeneration and repair are influenced by complex interactions between muscle fibers and surrounding connective tissue, which includes fibroblasts and other cell types that contribute to the fibrotic response observed in dystrophic muscles. This fibrotic response not only replaces lost muscle fibers with fibrous tissue but also disrupts the normal architecture of muscle, impairing function and regeneration (Wallace and McNally, 2009) [2].

The role of oxidative stress also emerges as a significant factor in the pathophysiology of muscular dystrophy. The interactions between genetic defects and disruptions in the normal production of free radicals contribute to muscle degeneration. For instance, in Duchenne muscular dystrophy (DMD), the deficiency of dystrophin leads to altered free radical production, which exacerbates muscle damage and impairs repair mechanisms (Tidball and Wehling-Henricks, 2007) [27].

In summary, the mechanisms underlying muscular dystrophy are multifaceted and include not only cell-autonomous defects due to genetic mutations but also critical non-cell autonomous interactions with surrounding tissues. These interactions involve immune responses, oxidative stress, and the role of stem/progenitor cells, all of which contribute to the complex pathology of muscular dystrophies and present potential avenues for therapeutic intervention.

5 Current and Emerging Therapies ​

5.1 Gene Therapy Approaches ​

Muscular dystrophies (MDs) are a heterogeneous group of genetic disorders characterized by progressive muscle weakness and wasting, primarily resulting from mutations in genes that encode proteins essential for muscle function. The most prevalent form is Duchenne muscular dystrophy (DMD), which is linked to mutations in the dystrophin gene. The pathophysiology of muscular dystrophies involves various mechanisms, including defects in the structural components of myofibers, leading to muscle degeneration and weakness [28].

The genetic basis of muscular dystrophies is diverse, with over 50 distinct genes identified as causative. These mutations can lead to several pathological mechanisms, such as glycosylation abnormalities, defects in the dystrophin-glycoprotein complex, and issues related to the structural integrity of muscle fibers [7].

Current therapeutic strategies for muscular dystrophies are largely supportive, focusing on symptom management. However, recent advances have led to the development of gene therapy approaches that aim to correct the underlying genetic defects. These include conventional gene replacement strategies, RNA-based technologies, and pharmacological interventions [28].

Gene therapy for muscular dystrophies, particularly DMD, has gained momentum with several innovative strategies being explored. Antisense-mediated exon skipping has shown promising results in clinical trials, allowing for the restoration of the reading frame in the dystrophin gene, thereby enabling the production of functional dystrophin protein [29]. Moreover, the use of adeno-associated viral (AAV) vectors has emerged as a significant method for delivering therapeutic genes directly to muscle tissues [30].

Cell-based therapies are also being investigated as potential treatments for muscular dystrophies. These approaches involve the transplantation of myogenic stem cells or genetically modified cells to regenerate damaged muscle fibers. Combining gene therapy with stem cell therapy is a promising strategy that may enhance the efficacy of treatment by allowing for autologous transplantation of corrected cells [31].

Overall, while significant progress has been made in understanding the mechanisms of muscular dystrophies and developing gene therapy approaches, challenges remain in ensuring effective delivery, minimizing immune responses, and achieving long-term benefits for patients [5]. The ongoing research continues to focus on refining these strategies to provide more effective and potentially curative treatments for individuals affected by muscular dystrophies.

5.2 Pharmacological Interventions ​

Muscular dystrophy encompasses a heterogeneous group of genetic disorders characterized by progressive muscle weakness and atrophy, primarily due to mutations in genes responsible for muscle function. The underlying mechanisms of muscular dystrophy are complex and involve various biochemical anomalies, membrane defects, and genetic factors.

The pathogenesis of muscular dystrophies is primarily linked to mutations in over 50 distinct genes, which can result in altered protein production essential for muscle integrity and function. For instance, Duchenne muscular dystrophy (DMD), the most common form, is caused by mutations in the dystrophin gene, leading to the absence of dystrophin, a protein critical for maintaining muscle cell stability during contraction [5]. The resulting muscle damage is compounded by inflammatory processes, oxidative stress, and impaired muscle repair mechanisms [32].

Pharmacological interventions for muscular dystrophies have historically been limited, with corticosteroids being the primary treatment option to alleviate symptoms and slow disease progression. These steroids can help manage muscle weakness but come with significant side effects [33]. Recent advances in research have opened avenues for novel therapies that aim to address the root causes of muscular dystrophy rather than merely managing symptoms. For example, gene therapy approaches, including exon-skipping techniques and the use of adeno-associated viral vectors, are being explored to correct the underlying genetic defects in muscle cells [34].

Moreover, the use of nitric oxide as a therapeutic agent has garnered attention due to its role in muscle repair and function. Nitric oxide is involved in various signaling pathways that regulate muscle growth and regeneration, presenting a potential alternative treatment avenue [35]. Additionally, recent studies have highlighted the potential of induced pluripotent stem cells (iPSCs) as a means to regenerate muscle tissue by providing a source of myogenic progenitors capable of differentiating into muscle cells [32].

Current pharmacological strategies also include the development of anti-inflammatory agents and antioxidants aimed at mitigating the secondary damage caused by inflammatory responses in muscular dystrophy [32]. Furthermore, there is ongoing research into mutation-specific therapies that target the unique genetic mutations present in different forms of muscular dystrophy, which may lead to more effective and personalized treatment options [36].

In summary, the mechanisms of muscular dystrophy are multifaceted, involving genetic mutations that disrupt muscle function and lead to progressive degeneration. The therapeutic landscape is evolving, with promising pharmacological interventions being developed that focus on correcting genetic defects, enhancing muscle repair, and addressing the inflammatory components of the disease. The future of treatment for muscular dystrophies holds potential for more effective and targeted therapies, moving beyond symptom management to address the underlying causes of these debilitating conditions.

5.3 Stem Cell Therapy ​

Muscular dystrophies (MDs) are a group of genetically heterogeneous disorders characterized by progressive muscle weakness and degeneration due to mutations in genes responsible for structural proteins in muscle fibers. The primary mechanism underlying these conditions often involves the deficiency or dysfunction of critical proteins that maintain muscle integrity, such as dystrophin in Duchenne muscular dystrophy (DMD) [37]. The absence of these proteins leads to muscle fiber breakdown, inflammation, and ultimately, loss of muscle function.

Current therapeutic approaches for MDs include oligonucleotide-based gene therapies aimed at restoring the expression of disease-related proteins. However, these methods have shown limited efficacy and are unlikely to provide a complete cure [38]. Stem cell therapy has emerged as a promising avenue in the treatment of MDs, particularly due to its potential to regenerate damaged muscle tissue and replenish the muscle stem cell pool [39].

Stem cell therapy for MDs involves several strategies, including the use of myogenic stem cells, which can differentiate into muscle cells and contribute to muscle repair. Various types of stem cells have been explored, including myoblasts, mesoangioblasts, and induced pluripotent stem cells (iPSCs) [37]. The use of iPSCs is particularly noteworthy as they can be generated from patient-derived cells, allowing for personalized treatment approaches [40].

Despite the promise of stem cell therapy, significant challenges remain. These include issues related to cell engraftment, delivery efficiency, and the risk of immune rejection [41]. Moreover, long-term safety and the potential for tumorigenicity must be thoroughly evaluated before these therapies can be considered viable treatment options [41]. Recent advancements have highlighted the importance of creating a conducive muscular environment for effective cell engraftment, and innovations in bioengineering may facilitate these efforts [38].

In conclusion, while the mechanisms of muscular dystrophy are primarily linked to genetic mutations leading to the dysfunction of muscle proteins, emerging therapies, particularly stem cell therapy, hold potential for addressing these challenges. However, further research is necessary to optimize these approaches and overcome the existing barriers to effective treatment.

6 Future Directions in Research ​

6.1 Novel Therapeutic Targets ​

Muscular dystrophy encompasses a heterogeneous group of genetic disorders characterized by progressive muscle weakness and degeneration, with underlying mechanisms that are complex and multifaceted. The pathogenesis of muscular dystrophies has been linked to various genetic mutations affecting structural proteins, leading to aberrant signaling pathways and cellular dysfunction.

A significant mechanism involves the deficiency of dystrophin, a cytoskeletal protein crucial for maintaining muscle integrity. The absence of dystrophin triggers a cascade of pathological events, ultimately resulting in muscle necrosis. This understanding has transformed the diagnostic and therapeutic landscape, highlighting the potential for genetic therapies aimed at restoring dystrophin expression or compensating for its absence (Desnuelle 1994) [42].

Moreover, the role of genetic modifiers has been increasingly recognized in influencing the phenotypic variability among patients with muscular dystrophy. These modifiers can affect disease progression, such as the age of loss of ambulation and the severity of cardiac involvement, providing a basis for developing targeted therapies (Hightower & Alexander 2018) [43].

Recent studies have also identified microRNAs (miRNAs) as crucial regulators of gene expression in muscle tissues. These small non-coding RNAs can modulate multiple mRNA targets, contributing to the complexity of muscle regulation. Understanding the regulatory networks involving miRNAs could unveil new therapeutic targets, as these molecules may play pivotal roles in muscle development and pathology (Eisenberg et al. 2009) [44].

In terms of future directions, the application of model organisms, such as Drosophila melanogaster, offers valuable insights into the molecular pathways associated with muscular dystrophy. Genetic manipulations in these models have facilitated the exploration of disease mechanisms and the identification of novel therapeutic targets, enhancing our understanding of muscular dystrophy's progression (Zhao et al. 2025) [45].

The therapeutic landscape is evolving, with novel strategies emerging from advancements in gene therapy, pharmacological interventions, and stem cell research. These approaches aim to not only alleviate symptoms but also address the underlying causes of muscular dystrophy. For instance, gene therapy techniques like exon skipping and adeno-associated viral vectors are being explored to restore functional protein expression in affected muscles (Cossu & Sampaolesi 2004) [34].

Overall, the ongoing research into the mechanisms of muscular dystrophy is paving the way for innovative therapeutic targets, emphasizing the need for a comprehensive understanding of genetic, molecular, and cellular factors involved in these disorders. Collaboration between basic research and clinical applications will be crucial in developing effective treatments for muscular dystrophies, ultimately improving patient outcomes.

6.2 Biomarkers for Disease Progression ​

Muscular dystrophies are a heterogeneous group of genetic disorders characterized by progressive muscle degeneration and weakness. The underlying mechanisms of these diseases involve a variety of genetic mutations affecting numerous proteins essential for muscle structure and function. Key findings in the literature provide insights into the cellular and molecular mechanisms contributing to muscular dystrophy, which can be broadly categorized into genetic mutations, cellular signaling pathways, and the roles of satellite cells and neuromuscular junctions.

  1. Genetic Mutations: The muscular dystrophies are primarily caused by mutations in over 50 distinct genes, with the most notable being the dystrophin gene, whose mutations lead to Duchenne muscular dystrophy (DMD). These mutations result in a loss of dystrophin, a critical protein that stabilizes the muscle cell membrane during contraction. The absence of dystrophin leads to muscle cell damage, necrosis, and the eventual replacement of muscle tissue with fibrous and adipose tissue, contributing to progressive weakness and loss of function [1][5].

  2. Cellular Signaling Pathways: Aberrant activation of specific cellular signaling pathways plays a significant role in the pathogenesis of muscular dystrophies. For instance, the dysregulation of pathways related to muscle repair and regeneration is commonly observed. The loss of structural proteins like dystrophin not only disrupts mechanical stability but also affects intracellular signaling that is crucial for muscle maintenance and regeneration [46]. The activation of inflammatory pathways and oxidative stress also contributes to muscle degeneration [2].

  3. Satellite Cell Dysfunction: Satellite cells are crucial for muscle regeneration. In muscular dystrophies, the ability of these cells to proliferate and differentiate into myoblasts is often impaired. Studies have shown that mutations can lead to premature senescence of satellite cells, reducing their availability for muscle repair. For example, in limb-girdle muscular dystrophy type 2H, the absence of the E3 ubiquitin ligase TRIM32 was shown to cause defects in muscle regrowth and premature senescence of satellite cells [47].

  4. Neuromuscular Junction (NMJ) Alterations: The neuromuscular junction, which facilitates communication between nerves and muscles, is also affected in muscular dystrophies. Functional denervation at NMJs is a hallmark of both aging and muscular dystrophy, leading to further muscle atrophy. Changes in NMJ morphology and signaling have been documented, indicating that both pre- and post-synaptic factors contribute to muscle weakness [48].

  5. Biomarkers for Disease Progression: Identifying biomarkers for muscular dystrophy progression is crucial for monitoring disease status and evaluating therapeutic interventions. Biomarkers can include muscle enzymes, genetic markers, and indicators of inflammation or muscle damage. Understanding the molecular mechanisms behind these biomarkers may help in developing targeted therapies and improving patient outcomes [49].

In summary, the mechanisms underlying muscular dystrophies are complex and multifaceted, involving genetic mutations, dysregulated cellular signaling, satellite cell dysfunction, and alterations at the neuromuscular junction. Future research directions should focus on elucidating these mechanisms further, particularly in identifying effective biomarkers for disease progression and developing innovative therapeutic strategies that target the underlying genetic and molecular defects.

7 Conclusion ​

The exploration of muscular dystrophy has revealed a complex interplay of genetic, cellular, and environmental factors that contribute to the pathogenesis of these debilitating disorders. Key findings highlight the critical role of genetic mutations in proteins such as dystrophin and their impact on muscle integrity, alongside the significant influence of genetic modifiers and environmental factors on disease progression. Current research underscores the necessity of understanding both cell-autonomous and non-cell-autonomous mechanisms, including inflammation, extracellular matrix remodeling, and the role of satellite cells in muscle regeneration. The identification of novel therapeutic targets and biomarkers is essential for advancing treatment strategies. Future research should focus on enhancing gene therapy approaches, optimizing pharmacological interventions, and exploring the potential of stem cell therapies to provide effective and personalized treatments. As our understanding of muscular dystrophy deepens, there is hope for developing innovative therapies that can significantly improve the quality of life for affected individuals and their families.

References ​

  • [1] Fedik Rahimov;Louis M Kunkel. The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy.. The Journal of cell biology(IF=6.4). 2013. PMID:23671309. DOI: 10.1083/jcb.201212142.
  • [2] Gregory Q Wallace;Elizabeth M McNally. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies.. Annual review of physiology(IF=19.1). 2009. PMID:18808326. DOI: 10.1146/annurev.physiol.010908.163216.
  • [3] Rasna Sabharwal. The link between stress disorders and autonomic dysfunction in muscular dystrophy.. Frontiers in physiology(IF=3.4). 2014. PMID:24523698. DOI: 10.3389/fphys.2014.00025.
  • [4] Scott A Smith;Ryan M Downey;Jon W Williamson;Masaki Mizuno. Autonomic dysfunction in muscular dystrophy: a theoretical framework for muscle reflex involvement.. Frontiers in physiology(IF=3.4). 2014. PMID:24600397. DOI: 10.3389/fphys.2014.00047.
  • [5] Yulia Chulanova;Dor Breier;Dan Peer. Delivery of genetic medicines for muscular dystrophies.. Cell reports. Medicine(IF=10.6). 2025. PMID:39765231. DOI: 10.1016/j.xcrm.2024.101885.
  • [6] Hongkyun Kim;Matthew J Rogers;Janet E Richmond;Steven L McIntire. SNF-6 is an acetylcholine transporter interacting with the dystrophin complex in Caenorhabditis elegans.. Nature(IF=48.5). 2004. PMID:15318222. DOI: 10.1038/nature02798.
  • [7] Ichizo Nishino;Eijiro Ozawa. Muscular dystrophies.. Current opinion in neurology(IF=4.4). 2002. PMID:12351997. DOI: 10.1097/00019052-200210000-00004.
  • [8] Ermelinda Ceco;Elizabeth M McNally. Modifying muscular dystrophy through transforming growth factor-β.. The FEBS journal(IF=4.2). 2013. PMID:23551962. DOI: 10.1111/febs.12266.
  • [9] Mattia Quattrocelli;Melissa J Spencer;Elizabeth M McNally. Outside in: The matrix as a modifier of muscular dystrophy.. Biochimica et biophysica acta. Molecular cell research(IF=3.7). 2017. PMID:28011285. DOI: 10.1016/j.bbamcr.2016.12.020.
  • [10] P C G Onofre-Oliveira;A L F Santos;P M Martins;D Ayub-Guerrieri;M Vainzof. Differential expression of genes involved in the degeneration and regeneration pathways in mouse models for muscular dystrophies.. Neuromolecular medicine(IF=3.9). 2012. PMID:22362587. DOI: 10.1007/s12017-012-8172-3.
  • [11] Antonio L Serrano;Pura Muñoz-Cánoves. Fibrosis development in early-onset muscular dystrophies: Mechanisms and translational implications.. Seminars in cell & developmental biology(IF=6.0). 2017. PMID:27670721. DOI: 10.1016/j.semcdb.2016.09.013.
  • [12] Dimple Bansal;Kevin P Campbell. Dysferlin and the plasma membrane repair in muscular dystrophy.. Trends in cell biology(IF=18.1). 2004. PMID:15066638. DOI: 10.1016/j.tcb.2004.03.001.
  • [13] Ankita Tulangekar;Tamar E Sztal. Inflammation in Duchenne Muscular Dystrophy-Exploring the Role of Neutrophils in Muscle Damage and Regeneration.. Biomedicines(IF=3.9). 2021. PMID:34680483. DOI: 10.3390/biomedicines9101366.
  • [14] Niamh Mahon;Jeffrey C Glennon. The bi-directional relationship between sleep and inflammation in muscular dystrophies: A narrative review.. Neuroscience and biobehavioral reviews(IF=7.9). 2023. PMID:36870583. DOI: 10.1016/j.neubiorev.2023.105116.
  • [15] Jenna M Kastenschmidt;Gerald Coulis;Philip K Farahat;Phillip Pham;Rodolfo Rios;Therese T Cristal;Ali H Mannaa;Rachel E Ayer;Rayan Yahia;Archis A Deshpande;Brandon S Hughes;Adam K Savage;Carlee R Giesige;Scott Q Harper;Richard M Locksley;Tahseen Mozaffar;S Armando Villalta. A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis-associated gene expression.. Cell reports(IF=6.9). 2021. PMID:33852849. DOI: 10.1016/j.celrep.2021.108997.
  • [16] Salyan Bhattarai;Qian Li;Jun Ding;Feng Liang;Ekaterina Gusev;Orsolya Lapohos;Gregory J Fonseca;Eva Kaufmann;Maziar Divangahi;Basil J Petrof. TLR4 is a regulator of trained immunity in a murine model of Duchenne muscular dystrophy.. Nature communications(IF=15.7). 2022. PMID:35169163. DOI: 10.1038/s41467-022-28531-1.
  • [17] Gang Li;Dengqin He;Xiaojia Cai;Wen Guan;Yali Zhang;Jia-Qiang Wu;Hongliang Yao. Advances in the development of phosphodiesterase-4 inhibitors.. European journal of medicinal chemistry(IF=5.9). 2023. PMID:36809706. DOI: 10.1016/j.ejmech.2023.115195.
  • [18] Alan Rawls;Bridget K Diviak;Cameron I Smith;Grant W Severson;Sofia A Acosta;Jeanne Wilson-Rawls. Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies.. Biomolecules(IF=4.8). 2023. PMID:37892218. DOI: 10.3390/biom13101536.
  • [19] James G Tidball;Steven S Welc;Michelle Wehling-Henricks. Immunobiology of Inherited Muscular Dystrophies.. Comprehensive Physiology(IF=5.2). 2018. PMID:30215857. DOI: 10.1002/cphy.c170052.
  • [20] Pam M Van Ry;Tatiana M Fontelonga;Pamela Barraza-Flores;Apurva Sarathy;Andreia M Nunes;Dean J Burkin. ECM-Related Myopathies and Muscular Dystrophies: Pros and Cons of Protein Therapies.. Comprehensive Physiology(IF=5.2). 2017. PMID:28915335. DOI: 10.1002/cphy.c150033.
  • [21] Payam Mohassel;A Reghan Foley;Carsten G Bönnemann. Extracellular matrix-driven congenital muscular dystrophies.. Matrix biology : journal of the International Society for Matrix Biology(IF=4.8). 2018. PMID:29933045. DOI: 10.1016/j.matbio.2018.06.005.
  • [22] Jennifer M Petrosino;Andrew Leask;Federica Accornero. Genetic manipulation of CCN2/CTGF unveils cell-specific ECM-remodeling effects in injured skeletal muscle.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology(IF=4.2). 2019. PMID:30216109. DOI: 10.1096/fj.201800622RR.
  • [23] Ashlee M Long;Jason M Kwon;GaHyun Lee;Nina L Reiser;Lauren A Vaught;Joseph G O'Brien;Patrick G T Page;Michele Hadhazy;Joseph C Reynolds;Rachelle H Crosbie;Alexis R Demonbreun;Elizabeth M McNally. The extracellular matrix differentially directs myoblast motility and differentiation in distinct forms of muscular dystrophy: Dystrophic matrices alter myoblast motility.. Matrix biology : journal of the International Society for Matrix Biology(IF=4.8). 2024. PMID:38582404. DOI: 10.1016/j.matbio.2024.04.001.
  • [24] Ashling Holland;Sandra Murphy;Paul Dowling;Kay Ohlendieck. Pathoproteomic profiling of the skeletal muscle matrisome in dystrophinopathy associated myofibrosis.. Proteomics(IF=3.9). 2016. PMID:26256116. DOI: 10.1002/pmic.201500158.
  • [25] James G Tidball;Michelle Wehling-Henricks. Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy.. The Journal of physiology(IF=4.4). 2014. PMID:25194047. DOI: 10.1113/jphysiol.2014.274878.
  • [26] Aleksandra Klimczak;Urszula Kozlowska;Maciej Kurpisz. Muscle Stem/Progenitor Cells and Mesenchymal Stem Cells of Bone Marrow Origin for Skeletal Muscle Regeneration in Muscular Dystrophies.. Archivum immunologiae et therapiae experimentalis(IF=3.9). 2018. PMID:29536116. DOI: 10.1007/s00005-018-0509-7.
  • [27] James G Tidball;Michelle Wehling-Henricks. The role of free radicals in the pathophysiology of muscular dystrophy.. Journal of applied physiology (Bethesda, Md. : 1985)(IF=3.3). 2007. PMID:17095633. DOI: 10.1152/japplphysiol.01145.2006.
  • [28] Aurélie Goyenvalle;Jane T Seto;Kay E Davies;Jeffrey Chamberlain. Therapeutic approaches to muscular dystrophy.. Human molecular genetics(IF=3.2). 2011. PMID:21436158. DOI: 10.1093/hmg/ddr105.
  • [29] Capucine Trollet;Takis Athanasopoulos;Linda Popplewell;Alberto Malerba;George Dickson. Gene therapy for muscular dystrophy: current progress and future prospects.. Expert opinion on biological therapy(IF=4.0). 2009. PMID:19527108. DOI: 10.1517/14712590903029164.
  • [30] Jane T Seto;Julian N Ramos;Lindsey Muir;Jeffrey S Chamberlain;Guy L Odom. Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.. Current gene therapy(IF=3.3). 2012. PMID:22533379. DOI: 10.2174/156652312800840603.
  • [31] Mirella Meregalli;Andrea Farini;Yvan Torrente. Combining stem cells and exon skipping strategy to treat muscular dystrophy.. Expert opinion on biological therapy(IF=4.0). 2008. PMID:18613758. DOI: 10.1517/14712598.8.8.1051.
  • [32] Shagun Singh;Tejpal Singh;Chaitanya Kunja;Navdeep S Dhoat;Narender K Dhania. Gene-editing, immunological and iPSCs based therapeutics for muscular dystrophy.. European journal of pharmacology(IF=4.7). 2021. PMID:34656607. DOI: 10.1016/j.ejphar.2021.174568.
  • [33] Kathryn R Wagner. Approaching a new age in Duchenne muscular dystrophy treatment.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics(IF=6.9). 2008. PMID:19019310. DOI: 10.1016/j.nurt.2008.08.013.
  • [34] Giulio Cossu;Maurilio Sampaolesi. New therapies for muscular dystrophy: cautious optimism.. Trends in molecular medicine(IF=13.8). 2004. PMID:15464452. DOI: 10.1016/j.molmed.2004.08.007.
  • [35] Patrizia Rovere-Querini;Emilio Clementi;Silvia Brunelli. Nitric oxide and muscle repair: multiple actions converging on therapeutic efficacy.. European journal of pharmacology(IF=4.7). 2014. PMID:24269596. DOI: .
  • [36] Hoda Abdel-Hamid;Paula R Clemens. Pharmacological therapies for muscular dystrophies.. Current opinion in neurology(IF=4.4). 2012. PMID:22941265. DOI: 10.1097/WCO.0b013e328357f44c.
  • [37] Congshan Sun;Carlo Serra;Gabsang Lee;Kathryn R Wagner. Stem cell-based therapies for Duchenne muscular dystrophy.. Experimental neurology(IF=4.2). 2020. PMID:31639376. DOI: 10.1016/j.expneurol.2019.113086.
  • [38] Norio Motohashi;Yuko Shimizu-Motohashi;Thomas C Roberts;Yoshitsugu Aoki. Potential Therapies Using Myogenic Stem Cells Combined with Bio-Engineering Approaches for Treatment of Muscular Dystrophies.. Cells(IF=5.2). 2019. PMID:31514443. DOI: 10.3390/cells8091066.
  • [39] Karlijn J Wilschut;Vivian B Ling;Harold S Bernstein. Concise review: stem cell therapy for muscular dystrophies.. Stem cells translational medicine(IF=4.9). 2012. PMID:23197695. DOI: 10.5966/sctm.2012-0071.
  • [40] Lubos Danisovic;Martina Culenova;Maria Csobonyeiova. Induced Pluripotent Stem Cells for Duchenne Muscular Dystrophy Modeling and Therapy.. Cells(IF=5.2). 2018. PMID:30544588. DOI: 10.3390/cells7120253.
  • [41] Agnieszka Łoboda;Józef Dulak. Cell therapy for Duchenne muscular dystrophy: promises, challenges, and controversies.. Cellular and molecular life sciences : CMLS(IF=6.2). 2025. PMID:41074937. DOI: 10.1007/s00018-025-05904-5.
  • [42] C Desnuelle. [Lessons of dystrophin].. Presse medicale (Paris, France : 1983)(IF=3.4). 1994. PMID:7937619. DOI: .
  • [43] Rylie M Hightower;Matthew S Alexander. Genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies.. Muscle & nerve(IF=3.1). 2018. PMID:28877560. DOI: 10.1002/mus.25953.
  • [44] Iris Eisenberg;Matthew S Alexander;Louis M Kunkel. miRNAS in normal and diseased skeletal muscle.. Journal of cellular and molecular medicine(IF=4.2). 2009. PMID:19175696. DOI: 10.1111/j.1582-4934.2008.00524.x.
  • [45] Yu Zhao;Yujie Wang;Ayibota Tulehalede;Zhu Meng;Lizhong Xu;Huashuai Bai;Junhui Sha;Wei Xie;Junhua Geng. Drosophila melanogaster: A Model Organism in Muscular Dystrophy Studies.. International journal of molecular sciences(IF=4.9). 2025. PMID:40003927. DOI: 10.3390/ijms26041459.
  • [46] Shephali Bhatnagar;Ashok Kumar. Therapeutic targeting of signaling pathways in muscular dystrophy.. Journal of molecular medicine (Berlin, Germany)(IF=4.2). 2010. PMID:19816663. DOI: 10.1007/s00109-009-0550-4.
  • [47] Elena Kudryashova;Irina Kramerova;Melissa J Spencer. Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H.. The Journal of clinical investigation(IF=13.6). 2012. PMID:22505452. DOI: .
  • [48] Rüdiger Rudolf;Muzamil Majid Khan;Siegfried Labeit;Michael R Deschenes. Degeneration of neuromuscular junction in age and dystrophy.. Frontiers in aging neuroscience(IF=4.5). 2014. PMID:24904412. DOI: 10.3389/fnagi.2014.00099.
  • [49] Sylwia Michorowska. Ataluren-Promising Therapeutic Premature Termination Codon Readthrough Frontrunner.. Pharmaceuticals (Basel, Switzerland)(IF=4.8). 2021. PMID:34451881. DOI: 10.3390/ph14080785.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Muscular Dystrophy · Genetic Mechanisms · Key Genes · Inflammation · Therapeutic Approaches

© 2025 MaltSci